DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: AZILECT

Summary for Tradename: AZILECT

Patents:5
Applicants:1
NDAs:1
Suppliers: see list2
drug
patent expirations by year for
 AZILECT

Pharmacology for Tradename: AZILECT

Clinical Trials for: AZILECT

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline
Status: Completed Condition: Parkinson's Disease

Azilect + Antidepressant Chart Review
Status: Completed Condition: Serotonin Syndrome

Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease
Status: Completed Condition: Parkinson's Disease

ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
Status: Completed Condition: Parkinson's Disease

Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor Fluctuations
Status: Completed Condition: Parkinson´s Disease

Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease
Status: Not yet recruiting Condition: Sleep Disturbances; Parkinsons's Disease

A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease
Status: Completed Condition: Parkinson's Disease

Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China
Status: Completed Condition: Parkinson's Disease

Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea
Status: Completed Condition: Parkinson's Disease

A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients
Status: Active, not recruiting Condition: Parkinson's Disease

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva
AZILECT
rasagiline mesylate
TABLET;ORAL021641May 16, 2006RXNo<disabled><disabled>
Teva
AZILECT
rasagiline mesylate
TABLET;ORAL021641May 16, 2006RXNo5,453,446<disabled><disabled>
Teva
AZILECT
rasagiline mesylate
TABLET;ORAL021641May 16, 2006RXNo5,532,415<disabled>Y<disabled>
Teva
AZILECT
rasagiline mesylate
TABLET;ORAL021641May 16, 2006RXNo6,126,968<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: AZILECT

Drugname Dosage Strength RLD Submissiondate
rasagiline mesylateTablets0.5 mg and 1 mgAzilect5/17/2010

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc